These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 18005503

  • 21. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 22. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
    Schmoelzer I, de Campo A, Pressl H, Stelzl H, Dittrich P, Oettl K, Wascher TC.
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
    [Abstract] [Full Text] [Related]

  • 23. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 24. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 25. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 26. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes.
    Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH.
    Diabetes Res Clin Pract; 2006 Feb 05; 71(2):131-9. PubMed ID: 16054266
    [Abstract] [Full Text] [Related]

  • 27. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.
    Mukherjee AK, Reddy VS, Shah S, Jhingan AK, Ramakrishnan P, Prusty V, Singh NS.
    J Indian Med Assoc; 2009 Jul 05; 107(7):464-70. PubMed ID: 20112854
    [Abstract] [Full Text] [Related]

  • 28. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov 05; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 29. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy.
    Jang HC, Lee SR, Vaz JA.
    Diabetes Obes Metab; 2009 Jan 05; 11(1):20-6. PubMed ID: 18479469
    [Abstract] [Full Text] [Related]

  • 30. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J.
    Diabetes Care; 2006 Sep 05; 29(9):2095-101. PubMed ID: 16936159
    [Abstract] [Full Text] [Related]

  • 31. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM, Noble S, Goa KL.
    Drugs; 2002 Sep 05; 62(13):1945-81. PubMed ID: 12215068
    [Abstract] [Full Text] [Related]

  • 32. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.
    Esteghamati A, Rajabian R, Amini M, Bahrami A, Khamseh ME, Afkhami-Ardekani M, Rizi EP.
    Endokrynol Pol; 2010 Sep 05; 61(4):364-70. PubMed ID: 20806180
    [Abstract] [Full Text] [Related]

  • 33. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial.
    Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall MA, Vesterager A, Wollmer P, Roberts A.
    Diabet Med; 2009 Mar 05; 26(3):260-7. PubMed ID: 19317821
    [Abstract] [Full Text] [Related]

  • 34. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.
    Exp Clin Endocrinol Diabetes; 2008 May 05; 116(5):282-8. PubMed ID: 18484560
    [Abstract] [Full Text] [Related]

  • 35. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes.
    Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M, Exubera Phase 3 Study Group.
    Int J Clin Pract; 2007 Oct 05; 61(10):1614-25. PubMed ID: 17877648
    [Abstract] [Full Text] [Related]

  • 36. Factors associated with switching from oral hypoglycaemic agents to insulin therapy.
    Spoelstra JA, Stol RP, de Bruyne MC, Erkens JA, Herings RM, Leufkens HG, Grobbee DE.
    Neth J Med; 2002 Jul 05; 60(6):243-8. PubMed ID: 12365467
    [Abstract] [Full Text] [Related]

  • 37. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ, Ligthelm R, Christiansen JS, Liebl A.
    Diabetes Obes Metab; 2007 Sep 05; 9(5):630-9. PubMed ID: 17697056
    [Abstract] [Full Text] [Related]

  • 38. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C, Shimizu T, Arakawa M, Mita T, Fujitani Y, Watada H, Kawamori R, Hirose T.
    Diabetes Res Clin Pract; 2009 Oct 05; 86(1):31-6. PubMed ID: 19692134
    [Abstract] [Full Text] [Related]

  • 39. A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes.
    Meneilly GS.
    Diabetes Obes Metab; 2007 Sep 05; 9(5):754-5. PubMed ID: 17697065
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of biphasic insulin aspart 30/70 in the treatment of patients with type 2 diabetes mellitus.
    Durán García S, de Alaiz RA, Bayort Fernández JA, Hernández Herrero C, Manzano García G, Pumar López A.
    Endocrinol Nutr; 2008 Apr 05; 55(4):159-64. PubMed ID: 22975451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.